Loading clinical trials...
Loading clinical trials...
A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies
Conditions
Interventions
ASP9853
Docetaxel
+1 more
Locations
4
United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Center
Detroit, Michigan, United States
Sarah Cannon Research Institute
Nashville, Tennessee, United States
Start Date
August 28, 2012
Primary Completion Date
June 11, 2014
Completion Date
June 11, 2014
Last Updated
November 7, 2024
Lead Sponsor
Astellas Pharma Global Development, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions